Patents Assigned to Novartis Vaccines and Diagnostics
-
Patent number: 8388942Abstract: Improved methods for purification and recovery of interferon-beta (IFN-?) and compositions comprising substantially monomeric IFN-? are provided. In one purification method, substantially purified IFN-? or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-?, residual guanidine HCl is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-?.Type: GrantFiled: April 29, 2008Date of Patent: March 5, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Sidney N Wolfe, Bret A Shirley, Susan Babuka, Dennis Fordham, Irina Esikova
-
Patent number: 8377446Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.Type: GrantFiled: December 16, 2011Date of Patent: February 19, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Marco Soriani, Isabella Santi
-
Patent number: 8361477Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminum phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.Type: GrantFiled: August 29, 2011Date of Patent: January 29, 2013Assignee: Novartis Vaccines and Diagnostics GmbHInventor: Astrid Borkowski
-
Publication number: 20130011405Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: September 12, 2012Publication date: January 10, 2013Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst, Sharon Lea Aukerman, Daniel E. Lopes de Menezes
-
Publication number: 20130004531Abstract: Disclosed herein are various polypeptides that can be included in immunogenic compositions specific for pathogenic E. coli strains. The polypeptides have cellular locations which render them accessible to the immune system. The genes encoding the polypeptides were initially identified as being present in uropathogenic strain 536 but absent from non-pathogenic strains.Type: ApplicationFiled: September 4, 2012Publication date: January 3, 2013Applicants: Robert Koch Institute, Novartis Vaccines and Diagnostics SRLInventors: Francesco BERLANDA SCORZA, Maria Rita Fontana, Danilo Gomes Moriel, Mariagrazia Pizza, Laura Serino, Jörg Hacker
-
Patent number: 8333958Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.Type: GrantFiled: January 11, 2011Date of Patent: December 18, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Bret A Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
-
Publication number: 20120315292Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: ApplicationFiled: March 2, 2012Publication date: December 13, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Publication number: 20120308569Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.Type: ApplicationFiled: June 7, 2012Publication date: December 6, 2012Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.Inventors: Vivien W. CHAN, Jaime Escobedo, Pablo Dominguez Garcia, Rhonda Hansen, Joerg Kaufmann, Giulia C. Kennedy, George Lamson, Edward J. Moler, Filippo Randazzo, Christoph Reinhard, Julie Sudduth-Klinger
-
Patent number: 8318791Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.Type: GrantFiled: June 5, 2009Date of Patent: November 27, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
-
Publication number: 20120289464Abstract: The present invention provides a unit dose composition comprising 0.2 ?g/kg to 48 ?g/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.Type: ApplicationFiled: April 15, 2011Publication date: November 15, 2012Applicant: Novartis Vaccines and Diagnostics, Inc.Inventor: Martha Jo Whitehouse
-
Publication number: 20120288501Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.Type: ApplicationFiled: July 24, 2012Publication date: November 15, 2012Applicant: Novartis Vaccines and Diagnostics, Inc. formerly known as Chiron CorporationInventors: Payman Amiri, Wendy Fantl, Barry Haskell Levine, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Sharadha Subramanian, Leonard Sung
-
Patent number: 8309139Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.Type: GrantFiled: April 18, 2006Date of Patent: November 13, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
-
Publication number: 20120276129Abstract: This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and/or nucleic acids.Type: ApplicationFiled: February 24, 2012Publication date: November 1, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Cesira Galeotti, Guido Grandi, Vega Masignani, Mariarosa Mora, Mariagrazia Pizza, Rino Rappuoli, Guilio Ratti, Vincenzo Scarlato, Maria Scarselli
-
Publication number: 20120269840Abstract: The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.Type: ApplicationFiled: April 27, 2012Publication date: October 25, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.Inventors: Susan W. BARNETT, Jan ZUR MEGEDE, Indresh SRIVASTAVA, Ying LIAN, Karin HARTOG, Hong LIU, Catherine GREER, Mark SELBY, Christopher WALKER
-
Publication number: 20120269851Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.Type: ApplicationFiled: February 17, 2012Publication date: October 25, 2012Applicants: University of Stellenbosch, NOVARTIS VACCINES & DIAGNOSTICS, INC.Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
-
Patent number: 8277810Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: GrantFiled: October 31, 2007Date of Patent: October 2, 2012Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst
-
Publication number: 20120244182Abstract: The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.Type: ApplicationFiled: June 4, 2012Publication date: September 27, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventor: Nicholas M. VALIANTE
-
Patent number: 8263394Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.Type: GrantFiled: January 23, 2008Date of Patent: September 11, 2012Assignee: Novartis Vaccines & Diagnostics Inc.Inventors: Jan zur Megede, Susan W. Barnett
-
Publication number: 20120219578Abstract: This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria Neisseria meningitidis B. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids). Additionally, this invention provides antibodies which bind to the proteins, polypeptides, and/or fragments. This invention further provides expression vectors useful for making the proteins, polypeptides, and/or fragments, as well as host cells transformed with such vectors. This invention also provides compositions of the proteins, polypeptides, fragments, and/or nucleic acids, for use as vaccines, diagnostic reagents, immunogenic compositions, and the like. Methods of making the compositions and methods of treatment with the compositions are also provided. This invention also provides methods of detecting the proteins, polypeptides, fragments, and/or nucleic acids.Type: ApplicationFiled: February 24, 2012Publication date: August 30, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Cesira GALEOTTI, Guido Grandi, Vega Masignani, Mariarosa Mora, Mariagrazia Pizza, Rino Rappuoli, Guilio Ratti, Vincenzo Scarlato, Maria Scarselli
-
Publication number: 20120207778Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences.Type: ApplicationFiled: February 16, 2012Publication date: August 16, 2012Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.Inventors: John Telford, Vega Masignani, Immaculada Margarit Y Ros, Guido Grandi, Claire Fraser, Hervé Tettelin